Vennerstrom J L, Dong Y, Andersen S L, Ager A L, Fu H, Miller R E, Wesche D L, Kyle D E, Gerena L, Walters S M, Wood J K, Edwards G, Holme A D, McLean W G, Milhous W K
College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.
J Med Chem. 2000 Jul 13;43(14):2753-8. doi: 10.1021/jm0000766.
Sixteen alkyl-substituted dispiro-1,2,4,5-tetraoxanes (7,8,15, 16-tetraoxadispiro[5.2.5.2]hexadecanes) were synthesized to explore dispiro-1,2,4,5-tetraoxane SAR and to identify tetraoxanes with better oral antimalarial activity than prototype tetraoxane 1 (WR 148999). The tetraoxanes were prepared either by peroxidation of the corresponding cyclohexanone derivatives in H(2)SO(4)/CH(3)CN or by ozonolysis of the corresponding cyclohexanone methyl oximes. Those tetraoxanes with alkyl substituents at the 1 and 10 positions were formed as single stereoisomers, whereas the five tetraoxanes formed without the stereochemical control provided by alkyl groups at the 1 and 10 positions were isolated as mixtures of diastereomers. Three of the sixteen tetraoxanes were inactive (IC(50)'s > 1000 nM), but five (2, 6, 10, 11, 12) had IC(50)'s between 10 and 30 nM against the chloroquine-sensitive D6 and chloroquine-resistant W2 clones of Plasmodium falciparum compared to corresponding IC(50)'s of 55 and 32 nM for 1 and 8.4 and 7.3 nM for artemisinin. We suggest that tetraoxanes 13, 16, and 17 were inactive and tetraoxanes 4 and 7 were weakly active due to steric effects preventing or hindering peroxide bond access to parasite heme. Tetraoxanes 1, 10, 11, and 14, along with artemisinin and arteether as controls, were administered po b.i.d. (128 mg/kg/day) to P. berghei-infected mice on days 3, 4, and 5 post-infection. At this dose, tetraoxanes 10, 11, and 14 cured between 40% and 60% of the infected animals. In comparison, artemisinin and tetraoxane 1 produced no cures, whereas arteether cured 100% of the infected animals. There was no apparent relationship between tetraoxane structure and in vitro neurotoxicity, nor was there any correlation between antimalarial activity and neurotoxicity for these seventeen tetraoxanes.
合成了16种烷基取代的二螺-1,2,4,5-四氧杂环己烷(7,8,15,16-四氧杂二螺[5.2.5.2]十六烷),以探索二螺-1,2,4,5-四氧杂环己烷的构效关系,并鉴定出比原型四氧杂环己烷1(WR 148999)具有更好口服抗疟活性的四氧杂环己烷。这些四氧杂环己烷可通过在H₂SO₄/CH₃CN中对相应环己酮衍生物进行过氧化反应,或通过对相应环己酮甲基肟进行臭氧分解反应来制备。那些在1位和10位带有烷基取代基的四氧杂环己烷以单一立体异构体形式形成,而在没有1位和10位烷基提供的立体化学控制下形成的5种四氧杂环己烷则作为非对映异构体混合物被分离出来。16种四氧杂环己烷中有3种无活性(IC₅₀>1000 nM),但有5种(2、6、10、11、12)对恶性疟原虫氯喹敏感株D6和氯喹耐药株W2的IC₅₀在10至30 nM之间,相比之下,1的相应IC₅₀为55和32 nM,青蒿素的为8.4和7.3 nM。我们认为四氧杂环己烷13、16和17无活性,四氧杂环己烷4和7活性较弱是由于空间效应阻止或阻碍过氧键接近寄生虫血红素。在感染后第3、4和5天,将四氧杂环己烷1、10、11和14,以及作为对照的青蒿素和蒿乙醚以口服方式每日两次(128 mg/kg/天)给予感染伯氏疟原虫的小鼠。在此剂量下,四氧杂环己烷10、11和14使40%至60% 的感染动物痊愈。相比之下,青蒿素和四氧杂环己烷1未能治愈任何动物,而蒿乙醚使100% 的感染动物痊愈。对于这17种四氧杂环己烷,其结构与体外神经毒性之间没有明显关系,抗疟活性与神经毒性之间也没有相关性。